In addition, two other novel glycosphingolipids were isolated from the mouse stomach epithelium that were found to be nonbinding with regard to H. pylori. The first was a pentaglycosylceramide, GalNAcβ3Galα3(Fucα2)Galβ4Glcβ1Cer, in which the isoglobo tetrasaccharide has been combined with Fucα2 to yield an isoglobotetraosylceramide with an internal blood group B determinant. The second one was an elongated fucosyl-gangliotetraosylceramide, GalNAcβ3(Fucα2)Galβ3GalNAcβ4Galβ4Glcβ1Cer.
Introduction
Bacterial adherence to target cells is an important virulence trait of pathogenic bacteria. The recognition of the Lewis b blood group antigen (Fucα2Galβ3(Fucα4)GlcNAc; Le b ) by certain strains of Helicobacter pylori was reported over a decade ago (Borén et al. 1993 ), and subsequently the cognate H. pylori Le bbinding adhesin BabA (blood group antigen binding adhesin) was identified (Ilver et al. 1998) . H. pylori strains expressing BabA together with the vacuolating cytotoxin VacA and the cytotoxin-associated antigen CagA (triple positive strains) are highly associated with severe gastric diseases, as peptic ulcer or gastric adenocarcinoma (Gerhard et al. 1999; Rad et al. 2002) .
Investigations of the molecular events following Le bmediated adhesion of H. pylori to the gastric epithelium were initially hampered by the lack of animal models since the Le b determinant is only present in humans. However, this obstacle was overcome when Falk et al. (1995) (Guruge et al. 1998) , while attachment of bacteria to the gastric pit cells was observed in the transgenic Le b mice only. The transgenic animals also had signs of inflammation in terms of chronic gastritis, loss of parietal cells and auto-antibodies to Lewis x carbohydrate epitopes.
The expression of glycoconjugates varies both quantitatively and qualitatively between different species, individuals of the same species, organs, and cells. Also, the glycosylation of the different parts of the gastrointestinal tract varies (reviewed in Hansson (1988) ). No comprehensive studies of the carbohydrate structures of glycoproteins or glycosphingolipids of the epithelial cells of mouse stomach have been reported. However, in the mouse small intestinal epithelium gangliotetraosylceramide (Galβ3GalNAcβ4Galβ4Glcβ1Cer) is one of the major glycosphingolipids Umesaki et al. 1981; Hansson et al. 1982) , and gangliotetraosylceramide having a terminal α2-linked Fuc (fucosyl-gangliotetraosylceramide; Fucα2Galβ3GalNAcβ4Galβ4Glcβ1Cer), i.e., a blood group H determinant-carrying compound, has also been described (Umesaki et al. 1981) , while no glycosphingolipids based on a type 1 core has been characterized in this tissue. Thus, at the glycosphingolipid level the α-1,3/4-fucosyltransferase expressed in the genetically engineered mice might use the blood group H determinant-carrying fucosylgangliotetraosylceramide as an acceptor. This possibility was examined in the present study by isolating neutral glycosphingolipids from stomachs of transgenic α-1,3/4-fucosyltransferase-expressing mice. A glycosphingolipid recognized by BabA-expressing H. pylori was isolated and characterized by mass spectrometry and proton NMR as Fucα2Galβ3(Fucα4)GalNAcβ4Galβ4Glcβ 1Cer, i.e., a Le b -like glycosphingolipid based on a ganglio core chain. In addition, two novel glycosphingolipids, GalNAcβ3Galα3(Fucα2)Galβ4 Glcβ1Cer representing a combined isoglobo-blood group B glycotope, and GalNAcβ3(Fucα2)Galβ3GalNAcβ4Galβ4 Glcβ1Cer representing an elongated FucGgO4, were isolated and characterized, but were found to be nonbinding with regard to H. pylori.
Results

Glycosphingolipid preparations and binding of H. pylori
From 3.84 g dry weight transgenic α-1,3/4-fucosyltransferaseexpressing mouse stomach tissue, 167 mg (43.5 mg/g) total acid, and 29 mg (7.6 mg/g) total neutral glycosphingolipids were obtained. The major compounds of the acid fraction migrated in the regions of GM3 and GD3 on thin-layer chromatograms. No binding of the H. pylori strain J99, expressing the sialic acid binding SabA adhesin (Mahdavi et al. 2002) , to the acid glycosphingolipids was obtained, and this fraction was not further characterized.
When the total neutral fraction was analyzed by thin-layer chromatography and chemical detection, the only compound visualized was migrating in the monoglycosylceramide region (data not shown). No binding of H. pylori strain J99 to the total neutral glycosphingolipid fraction was observed. The total neutral fraction was initially separated on a silicic acid column giving 13.5 mg of pure monoglycosylceramides and 10 mg of more slow-migrating compounds. After separation of the fraction with slow-migrating compounds on Iatrobeads columns, 12 glycosphingolipid-containing fractions were obtained (designated fractions n1-n12; Figure 1 , lanes 2-13). The amounts of the obtained subfractions are given below the figure.
The glycosphingolipid-containing fractions obtained were tested for binding of BabA-expressing H. pylori strain J99. While the majority of the fractions were nonbinding, an interaction of H. pylori strain J99 with fractions n10 and n11 was obtained ( Figure 2B hexaglycosylceramide, but did not interact with fractions n10 and n11 of transgenic mouse stomach ( Figure 2C ). In contrast, the clone 96 FR2.10 monoclonal anti-Le b antibody used in the original publication (Falk et al. 1995) readily recognized fractions n10 and n11, along with binding to reference Le b hexaglycosylceramide, and also to reference Le y hexaglycosylceramide, Fucα2Galβ4(Fucα3)GlcNAcβ3Galβ4Glcβ1Cer ( Figure 2D ).
This differential binding of the monoclonal anti-Le b antibodies suggested that the structure of the H. pylori-binding compound in fractions n10 and n11 was nonidentical to the Le b hexaglycosylceramide. In order to characterize the bindingactive compound, fraction n11 was analyzed by mass spectrometry and proton NMR, as described below. In addition, fractions n9, n10, and n12 were characterized by mass spectrometry and proton NMR. Thus, negative ion FAB mass spectrometry of fraction n11 showed a mixture of two glycosphingolipids with Fuc-Hex-(Fuc)HexNAc-Hex-Hex and HexNAc-HexNAcHex-Hex-Hex carbohydrate sequence, respectively.
Negative ion FAB mass spectrometry of fractions n9, n10, and n12
The negative ion FAB mass spectra of fractions n9 and n10 (not shown) were very similar and both had a series of molecular ions at m/z 1428-1540, corresponding to a glycosphingolipid with Hex3-HexNAc2 composition com- Proton NMR spectroscopy Figure 5 shows the anomeric regions of the 600 MHz proton NMR spectra of three different fractions from the FVB/N transgenic mouse stomach. The earliest fraction (n9) is dominated by the Forssman glycolipid (GalNAcα3GalNAcβ3Galα4Galβ4Glcβ1Cer) as shown in the top trace and detailed in Table I . Briefly, the two α-signals at 4.783 ppm and 4.696 ppm stem from Galα4 and GalNAcα3, respectively, whereas the three β-signals at 4.514 ppm, 4.255 ppm, and 4.17 ppm are attributable to GalNAcβ3, Galβ4, and Glcβ1, respectively (Dabrowski et al. 1980) . However, there are significant amounts (∼2%) also of a minor five-sugar species having two α-signals at 5.14 ppm and 4.87 ppm corresponding to internal Fucα2 (6-CH 3 at 1.04 ppm, not shown) and internal Galα3, respectively. Furthermore, two β-signals at 4.58 ppm and 4.36 ppm are ascribable to a terminal GalNAcβ3 and a fucose-linked Galβ4 whereas the Glcβ1 at the reducing end tentatively is assigned to the small β-signal seen at 4.21 ppm. These chemical shift values correspond closely to those of isoglobotetraosylceramide (iGb4, Table I ) except for the fucose-linked Galβ4, suggesting that the sugar sequence should read GalNAcβ3Galα3(Fucα2)Galβ4Glcβ1Cer (here termed iGb4-B). This is a novel shorter type 2-based version of the GalNAcβ3-Ganglio-B structure as is clearly reflected in the expected shift differences of the Fucα2 and Galβ3/4 residues of type 1-and type 2-based blood group B determinants (Table I) .
Fractions n10 and n11 both contain the same two compounds but in different proportions. In n10, the Forssman glycosphingolipid is very dominant (∼95%) whereas in n11 this glycosphingolipid is approximately equal to the second H. pylori-binding component as shown in the middle trace in Figure 5 . The anomeric resonances from the Forssman glycosphingolipid are readily identified by comparison with the previous fractions, thus leaving the remaining resonances in the anomeric region originating from the second component which from mass spectrometry is a hexaglycosylceramide with a Fuc-Hex-(Fuc)HexNAc-Hex-Hex carbohydrate sequence. The two α-signals at 4.896 ppm and 4.783 ppm are assigned to Fucα2 and Fucα4, respectively, of a Le b -like determinant where the latter fucose differs shiftwise relative to the corresponding residue of a regular Le b determinant by 0.026 ppm, as does its H5 resonance at 4.606 ppm (quartet) by −0.020 ppm (Table I, Clausen et al. 1985) , indicating a different environment. This supposition is further substantiated when the resonance at 4.560 ppm is inspected. This β-signal has a two-proton intensity suggesting that the Galβ3 resonance has merged with the HexNAcβ (Table I ; Le b -6). In order to establish the identity of the overlapping signals at 4.560 ppm, a COSY spectrum was acquired (not shown). Although suffering from an overall poor signal-tonoise ratio, the anomeric β-signals did give rise to sufficiently strong crosspeaks to allow the corresponding H2 resonances to be located. Thus, as expected two crosspeaks were found for the 4.560 ppm resonance yielding H2 resonances at 3.31 ppm and 3.76 ppm. The former resonance originates from Galβ3 but differs significantly from the corresponding H2 in the regular Fig. 4 . Negative ion FAB mass spectrum of fraction n12 from stomach of transgenic α-1,3/4-fucosyltransferase-expressing mice. Above the spectrum is an interpretation formula representing the species with t18:0-h16:0 to t18:0-h24:0 ceramides. The analysis was done as described in "Material and methods". 
Le
b hexaglycosylceramide found at 3.46 ppm (60 • C; Dabrowski et al. 1981) due to shielding effects mainly from the glycosidic oxygen between the HexNAc and Fucα4 residues, suggesting that this oxygen is axial with respect to the HexNAc, which thus would identify the residue as GalNAc. This is further corroborated by the value of the second H2 resonance (3.76 ppm) which is very close to the value found for, e.g., GalNAcβ4 of gangliotetraosylceramide (Galβ3GalNAcβ4Galβ4Glcβ1Cer, Koerner et al. 1983 ). However, final proof that the GalNAc is β4-linked is obtained when examining the shift of the anomeric resonance of the Galβ4 residue to which it is linked. This resonance is found at 4.199 ppm and again comparing with the corresponding sugar in gangliotetraosylceramide (Koerner et al. 1983 ) only a marginal difference is found for this signal as well as for the H2 signal at 4.21 ppm. Finally, the Glcβ1 signal is found at 4.185 ppm strongly overlapping with the H5 resonance (triplet appearance) from the Fucα2 at 4.188 ppm. The full sequence of this glycosphingolipid (here termed Ganglio-Le b -6) can thus be established as Fucα2Galβ3(Fucα4) GalNAcβ4Galβ4Glcβ1Cer. The final fraction examined by NMR (n12) reveals a single dominating compound also having six carbohydrate residues with the sequence HexNAc-(Fuc)-Hex-HexNAc-Hex-Hex according to mass spectrometry. The interpretation in this case was very straightforward since five of the six anomeric resonances correspond closely to those of fucosyl-gangliotetraosylceramide (Fucα2Galβ3GalNAcβ4Galβ4Glcβ1Cer) (FucGgO4, Table I ). Fucα2 is thus found at 4.937 ppm, Galβ3 at 4.328 ppm, GalNAcβ4 at 4.460 ppm, Galβ4 at 2.213 ppm, and Glcβ1 at 4.198 ppm. The sixth β-anomeric signal at 4.557 ppm must therefore be ascribed to the second HexNAc which by virtue of its chemical shift most likely corresponds to a terminal GalNAcβ3 residue. This is supported by the finding that the shift of the acetamido methyl resonance at 1.810 ppm (not shown) has suffered an upfield shift of 0.013 ppm relative to the corresponding resonance of the terminal GalNAcβ3 residue in the GalNAcβ3-Ganglio-B structure (Teneberg et al. 1994) due to crowding by the Fucα2.
Comparison of relative binding affinity
The relative binding affinity of H. pylori strain J99 for the traditional Le b hexaglycosylceramide and the Ganglio-Le b hexaglycosylceramide was estimated using dilutions of glycosphingolipids on thin-layer chromatograms, taking into account that the Ganglio-Le b -containing fraction n11 also contains the nonbinding Forssman glycosphingolipid (approximately 50% according to NMR). As shown in Figure 6 , H. pylori binding to fraction n11 still occurred when 0.4 µg was applied on the thinlayer plate (lane 5), giving a detection limit for the Ganglio-Le b hexaglycosylceramide at approximately 0.2 µg. In contrast, the bacteria readily bound to the regular Le b hexaglycosylceramide at 0.08 µg (lane 4), and the detection limit for this compound was approximately 0.02 µg (data not shown). 
Discussion
In the present study, an H. pylori-binding glycosphingolipid was isolated from stomach of transgenic α-1,3/4-fucosyltransferase-expressing mice and characterized by mass spectrometry and proton NMR as Fucα2Galβ3 (Fucα4)GalNAcβ4Galβ4Glcβ1Cer, i.e. a Le b -like glycosphingolipid on a ganglio core structure. The binding affinity of the H. pylori strain J99 for this ganglio-based Le b epitope was lower than for the "traditional" Le b epitope, indicating that a GalNAc instead of a GlcNAc is not optimal for the BabA adhesin. In this context, it should also be noted that the BabA adhesin of the J99 strain is of the generalist type and, in addition to the Le b and H type 1 epitopes, binds to the blood group A and B type 1 epitopes (Aspholm-Hurtig et al. 2004) . When using the specialist strain P466, with BabA recognizing the Le b and H type 1 epitopes only, no binding to the Ganglio-Le b hexaglycosylceramide was obtained (data not shown).
The occurrence of "ganglio-B," Galα3(Fucα2)Galβ 3GalNAcβ4Galβ4Glcβ1Cer, in rat bone marrow, spleen, thymus, gastric mucosa, and rat hepatoma ascites has been reported (Taki et al. 1985; Hansson et al. 1987) . However, the ganglio-based Le b -glycosphingolipid is to our knowledge a novel structure.
In addition, two novel glycosphingolipids were characterized. The first was a minor compound identified as GalNAcβ3Galα3(Fucα2)Galβ4Glcβ1Cer, i.e., a Fucα2-substituted isoglobotetraosylceramide having an internal blood group B determinant. The second one was an elongated fucosylgangliotetraosylceramide, GalNAcβ3(Fucα2)Galβ3GalNAcβ-4Galβ4Glcβ1Cer. None of these novel glycosphingolipds were recognized by H. pylori, and although isolated from transgenic α-1,3/4-fucosyltransferase-expressing mouse stomach, it is not likely that the human α-1,3/4-fucosyltransferase is involved in the synthesis of these two glycosphingolipids since no α3-or α4-linked fucose is present in these compounds.
The transgenic Le b mouse was established by the expression of a human α-1,3/4-fucosyltransferase in the gastric pit cell lineage of FVB/N transgenic mice. During the studies preceding the creation of the transgenic Le b mouse, the presence of an acceptor blood group H determinant in gastric pit cells and surface mucous cells of the FVB/N mice was established by binding of a monoclonal antibody directed against the blood group H type 2 determinant (Fucα2Galβ4GlcNAc). Monoclonal antibody clone 96 FR2.10 binding to histo-sections and isolated glycoproteins was also used to establish the creation of the Le b epitope upon the expression of the human α-1,3/4-fucosyltransferase in the pit cell lineage (Falk et al. 1995) .
In the chromatogram binding assay, the T218 anti-Le b monoclonal antibody bound only to reference Le b hexaglycosylceramide and did not recognize the H. pylori-binding glycosphingolipid of transgenic Le b mice stomach. In contrast, the H. pylori-binding glycosphingolipid was recognized by the clone 96 FR2.10 monoclonal antibody, along with binding to the reference Le b and Le y hexaglycosylceramides. Thus, the binding specificity of the clone 96 FR2.10 anti-Le b monoclonal antibody is broader, and it tolerates both a type 2 core chain (Galβ4GlcNAc) and a ganglio core chain (Galβ3GalNAc), in addition to the type 1 core chain (Galβ3GlcNAc) of Le b . Crossreactivity of the clone 96 FR2.10 monoclonal antibody with blood group H type 1 determinant (Fucα2Galβ3GlcNAc) has been reported previously (Good et al. 1992; Larson et al. 1999) .
The clone 96 FR2.10 monoclonal antibody was utilized to demonstrate the presence of the Le b epitope in a glycoprotein from the transgenic Le b mouse stomach by binding to stomach protein extracts (Falk et al. 1995 xenoantigen Galα3Galβ4GlcNAc, produced by the α-1,3-galactosyltransferase. Firstly, the level of the Galα3Galβ4GlcNAc epitope has been reduced by the introduction of an α-1,2-fucosyltransferase, which competes with the α-1,3-galactosyltransferase for the common N-acetyllactosamine (Galβ4GlcNAc) substrate (Costa et al. 1999) . Secondly, the α-1,3-galactosyltransferase gene has been inactivated, leading to elimination of the xenoantigen (Tearle et al. 1996; Phelps et al. 2003; Kolber-Simonds et al. 2004) . A recent biochemical characterization of small intestinal and pancreatic glycosphingolipids from galactosyltransferase knock-out pigs confirmed the absence of Galα3Galβ4GlcNAc-terminated compounds (Diswall et al. 2007) . The third approach is overexpression of lysosomal α-galactosidase, which also decreased the level of the Galα3Galβ4GlcNAc epitope (Osman et al. 1997 ).
In conclusion, manipulation of the glycome by the introduction of glycosyltransferases in transgenic animals may result in novel carbohydrate sequences. The resulting carbohydrate expression of transgenic animals has mainly been monitored by binding of antibodies and lectins (Shinkel et al. 1997; Phelps et al. 2003; Kolber-Simonds 2004) . However, as recently described by Manimala et al. (2007) , there are severe specificity problems with many carbohydrate-binding monoclonal antibodies currently in use. Thus, biochemical methods are still necessary for the characterization of carbohydrate sequences, and antibody binding data only are not sufficient.
Material and methods
Preparation of glycosphingolipids FVB/N transgenic mice, expressing the human α-1,3/4-fucosyltransferase gene in the stomachs, were used (Falk et al. 1995) . The mice were bred and kept at Astrid Fagreaus Laboratory in Stockholm, Sweden. They were kept on a 12 h light-dark cycle and water and food (standard pellet diet) was provided ad libitum. To ensure transgenicity, all breeding couples were tested for the presence of the transgene as described by Falk et al. (1995) . All animal experiments were approved by the local animal ethical committee at Karolinska Institutet.
The mice were sacrificed with cervical dislocation under inhalation anesthesia with isofluran and stomachs were recovered and kept at −70 • C. In total, stomach tissue was collected from 209 transgenic Le b -mice. Acid and neutral glycosphingolipids were isolated as described (Karlsson 1987) . Briefly, the pooled stomach tissue was lyophilized (dry weight 3.84 g), and then extracted in two steps in a Soxhlet apparatus with chloroform and methanol (2:1 and 1:9, by volume, respectively). The material obtained was subjected to mild alkaline hydrolysis and dialysis, followed by separation on a silicic acid column. Acid and neutral glycosphingolipid fractions were obtained by chromatography on a DEAE-cellulose column. In order to separate the neutral glycolipids from alkali-stable phospholipids, this fraction was acetylated and separated on a second silicic acid the molecule. Fatty acids with a 2-hydroxy group are denoted by the prefix h before the abbreviation, e.g., h16:0. For long chain bases, d denotes dihydroxy and t trihydroxy. Thus, d18:1 designates sphingosine (1,3-dihydroxy-2-aminooctadecene) and t18:0 phytosphingosine (1,3,4-trihydroxy-2-aminooctadecane).
